ST-Segment Yükselmesi Miyokard İnfarktüsülü Hastalarda Primer Perkütan Koroner Girişim Sonrası Anjiyografik Akışsızlık Fenomenini Öngürmede Başvuru Serum Albümin Düzeylerinin Yararı

Halit Acet; Faruk Ertaş; Mesut Aydın; Hasan Kaya; Murat Yüksel; Mehmet Zihni Bilik; Nihat Polat; Mehmet Ata Akıl; Abdulkadir Yıldız; Mehmet Özbek; Leyla Çiftçi; Necdet Ozaydoğdu

doi:10.5505/abantmedj.2015.42713

The Utility of the Serum Albumin Levels on Admission for Predicting Angiographic No Reflow After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction

Year 2015, , 230 - 238, 01.09.2015

Halit Acet Faruk Ertaş Mesut Aydın Hasan Kaya Murat Yüksel Mehmet Zihni Bilik Nihat Polat Mehmet Ata Akıl Abdulkadir Yıldız Mehmet Özbek Leyla Çiftçi Necdet Ozaydoğdu

https://doi.org/10.5505/abantmedj.2015.42713

Abstract

OBJECTIVE: Low serum albumin SA levels are associated with increased cardiovascular mortality. We investigated whether baseline SA levels are associated with no-reflow in patients undergoing primary percutaneous coronary intervention p-PCI . METHODS: STEMI patients treated by p-PCI were included in the study. The patients were followed during in hospital period. We defined angiographic no-reflow phenomenon as a coronary TIMI flow grade ≤2 after vessel re-canalized or TIMI flow grade 3 together with a final MBG < 2, in the same manner as was adopted in previous studies. The patients were divided into two groups according to the SA levels on admission, hypoalbuminemia group with SA3.5 g/dl.RESULTS: A total of 358 patients aged 62+14 years; 72% men who underwent p-PCI were enrolled in the study. Admission SA levels were significantly lower in the no-reflow group than in the normal-reflow group p

Keywords

Serum albumin level, no-reflow phenomenon, primary percutaneous coronary intervention, acute myocardial infarction

References

1. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. the primary angioplasty in myocardial infarction study group. N Engl J Med. 1993;328(10):673-679.
2. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse longterm outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol. 2000;36(4):1202-1209.
3. Lee CH, Tse HF. Microvascular obstruction after percutaneous coronary intervention. Catheter Cardiovasc Interv. 2010;75(3): 369-377.
4. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2008;72(7):950-957.
5. Peters T Jr. Serum albumin. Adv Protein Chem. 1985;37:161-245.
6. Nelson JJ, Liao D, Sharrett A, Folsom AR, Chambless LE, Shahar E, et al. Serum albumin level as a predictor of incident coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 2000; 151:468–477.
7. Gresele P, Deckmyn H, Huybrechts E, Vermylen J. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. Biochem Pharmacol. 1984;33(13):2083-2088.
8. Mikhailidis DP, Barradas MA, Maris A, Jeremy JY, Dandona P. Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease. J Clin Pathol. 1985;38(10):1166-1171.
9. Joles JA, Willekes-Koolschijn N, Koomans HA. Hypoalbuminemia causes high blood viscosity by increasing red cell lysophosphatidylcholine. Kidney Int. 1997;52(3):761-770.
10. Phillips A, Shaper AG, Whincup PH. Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. Lancet. 1989;2(8677):1434-1436.
11. Oduncu V, Erkol A, Karabay CY, et al. The prognostic value of serum albumin levels on admission in patients with acute STsegment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. Coron Artery Dis. 2013; 24(2):88-94.
12. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-13.
13. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients.Am J Cardiol1967;20:457– 64.
14. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI study group. N Engl J Med 1985;312:932e6.
15. Sorajja P, Gersh BJ, Costantini C, McLaughlin MG, Zimetbaum P, Cox DA, Garcia E, Tcheng JE, Mehran R, Lansky AJ, Kandzari DE, Grines CL, Stone GW. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 2005;26:667-674.
16-Gibson CM, Murphy SA, Morrow DA, et al. Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. Am Heart J 2004;148:336e40.)
17. Reffelmann T, Kloner RA. The no-reflow phenomenon: basic science and clinical correlates. Heart. 2002;87(2):162-168.
18. Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med. 2006;3(9):499-506.
19. Huczek Z, Kochman J, Filipiak KJ, et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol. 2005;46(2):284-290.
20. Ko YG, Jung JH, Park S, et al. Inflammatory and vasoactive factors in the aspirate from the culprit coronary artery of patients with acute myocardial infarction. Int J Cardiol. 2006;112(1):66-71.
21. Botto N, Sbrana S, Trianni G, et al. An increased plateletleukocytes interaction at the culprit site of coronary artery occlusion in acute myocardial infarction: a pathogenic role for ‘‘no-reflow’’ phenomenon? Int J Cardiol. 2007;117(1):123-130.
22. ZhangWJ, Frei B. Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. Cardiovasc Res. 2002;55(4):820-829.
23. Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004;17(6):432-437.
24. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003;108(19):2317-2322.
25. Kloner RA, Ganote CE, Jennings RB. The ‘‘noreflow’’ phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54(6):1496- 1508.
26. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2008; 72:950–957.
27. Lapenna D, Ciofani G, Ucchino S, Pierdomenico SD, Cuccurullo C, Giamberardino MA, et al. Serum albumin and biomolecular oxidative damage of human atherosclerotic plaques. Clin Biochem 2010; 43: 1458– 1460.
28. Halliwell B. Albumin: an important extracellular antioxidant? Biochem Pharmacol 1988; 37:569–571.
29. Gaar KA Jr, Taylor AE, Owens LJ, Guyton AC. Effect of capillary pressure and plasma protein on development of pulmonary edema. Am J Physiol 1967; 213:79–82.
30 Don BR, Kaysen GA. Serum albumin: relationship to inflammation and nutrition. Semin Dial 2004; 17:432– 437.
31 Chojkier M. Inhibition of albumin synthesis in chronic diseases: molecular mechanisms. J Clin Gastroenterol 2005; 39 (Suppl 2):143–146.
32 Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB. Risk factors for coronary heart disease and acute-phase proteins. A populationbased study. Eur Heart J 1999; 20:954–959.
33. Kaysen GA, Dubin JA, Muller HG, Rosales LM, Levin NW. and the HEMO study group. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. Kidney Int 2000; 58: 346–352.
34. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91(11):2844-2850.
35. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6): 448-454. Erratum in: N Engl J Med. 1999;340(17):1376.
36. Kinjo K, Sato H, Ohnishi Y, Hishida E, Nakatani D, Mizuno H, et al. Osaka acute coronary insufficiency study (OACIS) group. Impact of high-sensitivity Creactive protein on predicting long-term mortality of acute myocardial infarction. Am J Cardiol 2003; 91:931–935.
37. Hartopo AB, Gharini PP, Setianto BY. Low serum albumin levels and in-hospital adverse outcomes in acute coronary syndrome. Int Heart J. 2010;51(4):221- 226.
38. Polat N, Aydın M, Yıldız A, Acet H, Akıl MA, Bilik MZ, et al. The prognostic significance of serum albumin in patients with acute decompensated systolic heart failure Acta Cardiol 2014; 69(7): 648-654 doi:10.2143/AC.69.6.1000007
39. Narang R, Ridout D, Nonis C, Kooner JS. Serum calcium, phosphorus and albumin levels in relation to the angiographic severity of coronary artery disease. Int J Cardiol 1997; 60:73–79.